Clinical Trial Update: Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nonmyeloablative allogeneic stem cell transplantation followed by bortezomib in high-risk multiple myeloma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Maisonneuve-Rosemont Hospital | Conditions: Multiple Myeloma, High-Risk Cancer | Phase 2 | Status: COMPLETED